Exactly. Slow burn but as long as they don't go crazy with staff...

Exactly. Slow burn but as long as they don't go crazy with staff and overheads, you can't argue with the momentum this should achieve in terms of capturing market share. The next task is to ensure clinicians use these scans instead of ctpa as there is an overall decline in their use. The scan is by no means redundant - it is actually very good - but clinical practice may have shifted away from it in the US (perhaps because they didn't have access to Technegas!) But this just means the company has work on a few fronts. That being said I have confidence that they are going to capture the overwhelming majority of the current volume of scans which still reflects a massive revenue change from their pre-FDA level. Great buying at $1.80 imo, dyor.